X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (13367) 13367
Book Review (2195) 2195
Publication (1628) 1628
Conference Proceeding (45) 45
Book Chapter (40) 40
Dissertation (9) 9
Magazine Article (9) 9
Book / eBook (6) 6
Streaming Video (4) 4
Web Resource (4) 4
Data Set (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (12740) 12740
humans (12439) 12439
hepacivirus - genetics (6530) 6530
male (5956) 5956
female (5776) 5776
hepatitis c virus (5440) 5440
hepacivirus - drug effects (5322) 5322
middle aged (4983) 4983
hepatitis c (4837) 4837
antiviral agents - therapeutic use (4714) 4714
adult (4702) 4702
hepatitis c, chronic - drug therapy (4129) 4129
genotype (3717) 3717
gastroenterology & hepatology (3590) 3590
hepatitis (2977) 2977
treatment outcome (2904) 2904
drug therapy, combination (2700) 2700
infection (2692) 2692
hepatitis c - drug therapy (2626) 2626
hepatitis c, chronic - virology (2626) 2626
virology (2623) 2623
interferon-alpha - therapeutic use (2536) 2536
ribavirin - therapeutic use (2513) 2513
interferon (2488) 2488
antiviral agents - pharmacology (2428) 2428
ribavirin (2397) 2397
aged (2396) 2396
hepatitis c - virology (2323) 2323
infectious diseases (2260) 2260
health aspects (2231) 2231
hepacivirus - physiology (2048) 2048
hcv (1912) 1912
hepacivirus - isolation & purification (1870) 1870
virus diseases (1797) 1797
viral load (1705) 1705
rna, viral - blood (1667) 1667
antiviral agents (1618) 1618
viruses (1599) 1599
therapy (1533) 1533
hepacivirus - immunology (1525) 1525
infections (1517) 1517
antiviral agents - administration & dosage (1516) 1516
animals (1485) 1485
hepacivirus (1481) 1481
liver (1456) 1456
rna (1448) 1448
recombinant proteins (1424) 1424
analysis (1399) 1399
polyethylene glycols - therapeutic use (1372) 1372
virus-infection (1355) 1355
antiviral agents - adverse effects (1341) 1341
risk factors (1314) 1314
microbiology (1305) 1305
immunology (1270) 1270
replication (1260) 1260
pharmacology & pharmacy (1209) 1209
genetic aspects (1199) 1199
virus replication - drug effects (1183) 1183
plus ribavirin (1147) 1147
biological response modifiers (1134) 1134
care and treatment (1130) 1130
prevalence (1088) 1088
hiv (1087) 1087
abridged index medicus (1072) 1072
ribavirin - administration & dosage (1054) 1054
digestive system diseases (1052) 1052
hepatitis c - complications (1047) 1047
research (1042) 1042
hepatitis c, chronic - complications (1024) 1024
gastroenterology and hepatology (996) 996
interferon-alpha - administration & dosage (989) 989
cell line (971) 971
hepatitis c - epidemiology (964) 964
viral nonstructural proteins - antagonists & inhibitors (963) 963
hepatitis-c virus (927) 927
young adult (924) 924
retrospective studies (920) 920
time factors (904) 904
drug therapy (903) 903
research article (896) 896
adolescent (895) 895
cirrhosis (881) 881
genotypes (879) 879
viral nonstructural proteins - genetics (879) 879
hepacivirus - pathogenicity (859) 859
hepatocellular-carcinoma (857) 857
rna, viral - genetics (848) 848
medicine (840) 840
sustained virological response (833) 833
hepacivirus - classification (819) 819
hepacivirus - enzymology (813) 813
recombinant proteins - therapeutic use (775) 775
liver diseases (773) 773
hepatitis c - immunology (768) 768
antiviral agents - chemistry (757) 757
multidisciplinary sciences (749) 749
proteins (749) 749
biochemistry & molecular biology (746) 746
viral nonstructural proteins - metabolism (744) 744
hiv infections - complications (738) 738
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (12934) 12934
Chinese (99) 99
Japanese (60) 60
Russian (59) 59
German (58) 58
Spanish (46) 46
French (40) 40
Polish (29) 29
Hungarian (18) 18
Korean (13) 13
Italian (7) 7
Turkish (6) 6
Hebrew (5) 5
Dutch (4) 4
Croatian (2) 2
Czech (2) 2
Danish (2) 2
Norwegian (2) 2
Portuguese (2) 2
Serbian (2) 2
Ukrainian (2) 2
Bosnian (1) 1
Finnish (1) 1
Icelandic (1) 1
Romanian (1) 1
Slovak (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Gastroenterology, ISSN 0016-5085, 2015, Volume 149, Issue 3, pp. 649 - 659
Background & Aims There are no effective and safe treatments for chronic hepatitis C virus (HCV) infection of patients who have advanced liver disease. Methods... 
Gastroenterology and Hepatology | Liver Transplantation | Decompensated Cirrhosis | Hepatitis C Virus Infection | Fibrosing Cholestatic Hepatitis | C INFECTION | TRANSPLANTATION PATIENTS | RECIPIENTS | INTERFERON | THERAPY | ADEFOVIR DIPIVOXIL | CIRRHOSIS | GENOTYPE 1 INFECTION | OUTCOMES | GASTROENTEROLOGY & HEPATOLOGY | United States | Humans | Middle Aged | Fluorenes - therapeutic use | Liver Cirrhosis - mortality | Hepacivirus - genetics | Male | Cholestasis, Intrahepatic - drug therapy | Hepatitis C, Chronic - complications | Hepatitis C, Chronic - mortality | Time Factors | Female | Fluorenes - adverse effects | Uridine Monophosphate - adverse effects | Benzimidazoles - adverse effects | Drug Therapy, Combination | Cholestasis, Intrahepatic - virology | Benzimidazoles - therapeutic use | Uridine Monophosphate - therapeutic use | Hepacivirus - drug effects | Liver Cirrhosis - drug therapy | Liver Cirrhosis - diagnosis | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Genotype | Treatment Outcome | Hepatitis C, Chronic - diagnosis | Hepatitis C, Chronic - drug therapy | Disease Progression | Cholestasis, Intrahepatic - mortality | Hepacivirus - enzymology | Liver Cirrhosis - virology | Cholestasis, Intrahepatic - diagnosis | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Drug Combinations | Care and treatment | Liver diseases | Hepatitis C virus | Hepatitis C | Health aspects | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2015, Volume 373, Issue 8, pp. 705 - 713
Among patients coinfected with HIV-1 and HCV genotype 1 or 4 who were receiving effective antiretroviral therapy, treatment with 12 weeks of ledipasvir and... 
MEDICINE, GENERAL & INTERNAL | HEPATOCELLULAR-CARCINOMA | INTERFERON | THERAPY | HEPATITIS-C VIRUS | CIRRHOSIS | ALPHA-2A PLUS RIBAVIRIN | VETERANS | GENOTYPE 1 INFECTION | COHORT | LIVER-DISEASE | HIV-1 | Humans | Middle Aged | Drug Resistance, Viral | Fluorenes - therapeutic use | Hepacivirus - genetics | Male | RNA, Viral - blood | Hepatitis C, Chronic - complications | Viral Load | Female | Fluorenes - adverse effects | Uridine Monophosphate - adverse effects | Benzimidazoles - adverse effects | Drug Therapy, Combination | Benzimidazoles - therapeutic use | Uridine Monophosphate - therapeutic use | Hepacivirus - drug effects | Fluorenes - pharmacokinetics | Hepacivirus - isolation & purification | Anti-Retroviral Agents - therapeutic use | Antiviral Agents - therapeutic use | Benzimidazoles - pharmacokinetics | Genotype | Hepatitis C, Chronic - drug therapy | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | HIV Infections - complications | HIV Infections - drug therapy | Uridine Monophosphate - pharmacokinetics | Sofosbuvir | Care and treatment | Research | Hepatitis C virus | HIV infection | Emtricitabine | Headache | Antiretroviral drugs | Inhibitor drugs | Diarrhea | Fatigue | Patients | Efavirenz | Studies | Tenofovir | Cirrhosis | Genotype & phenotype | Hepatitis | Human immunodeficiency virus--HIV | Hepatitis C | Drug therapy | Genotypes | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2017, Volume 376, Issue 22, pp. 2134 - 2146
In two trials involving patients with hepatitis C in whom previous treatment with direct-acting antiviral agents failed, treatment for 12 weeks with... 
GENOTYPE 1 | MEDICINE, GENERAL & INTERNAL | THERAPY | HEPATITIS-C VIRUS | EFFICACY | PROTEASE INHIBITOR GS-9857 | RESISTANCE | DIRECT-ACTING ANTIVIRALS | OPEN-LABEL | COMBINATION | PHASE-2 TRIAL | Hepatitis C - drug therapy | Humans | Middle Aged | Drug Resistance, Viral | Hepacivirus - genetics | Male | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Aged, 80 and over | Adult | Female | Hepatitis C - complications | Sofosbuvir - adverse effects | Protease Inhibitors - therapeutic use | Hepacivirus - drug effects | Sofosbuvir - therapeutic use | Liver Cirrhosis - etiology | Antiviral Agents - therapeutic use | Genotype | Heterocyclic Compounds, 4 or More Rings - adverse effects | Macrocyclic Compounds - adverse effects | Macrocyclic Compounds - therapeutic use | Sulfonamides - therapeutic use | Antiviral Agents - adverse effects | Hepatitis C - virology | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Viral Nonstructural Proteins - antagonists & inhibitors | Drug Combinations | Care and treatment | Hepatitis C virus | Drug therapy | Patients | Health aspects | Headache | Antiretroviral drugs | Antiviral agents | Proteinase | Clinical trials | Diarrhea | Fatigue | Nausea | Cirrhosis | Hepatitis | Genotypes | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2015, Volume 373, Issue 8, pp. 714 - 725
Journal Article
Nature, ISSN 0028-0836, 11/2015, Volume 527, Issue 7577, pp. 245 - 248
Journal Article
Gastroenterology, ISSN 0016-5085, 2014, Volume 147, Issue 2, pp. 359 - 365.e1
Background & Aims The interferon-free regimen of ABT-450 (a protease inhibitor), ritonavir, ombitasvir (an NS5A inhibitor), dasabuvir (a non-nucleoside... 
Gastroenterology and Hepatology | IFN | PEARL-II | Ribavirin-Free | Interferon-Free Therapy | PLUS RIBAVIRIN | ABT-450/R-OMBITASVIR | VIRUS-INFECTION | TELAPREVIR | SOFOSBUVIR | CHRONIC HEPATITIS-C | COMBINATION | TRIAL | CIRRHOSIS | BOCEPREVIR | GASTROENTEROLOGY & HEPATOLOGY | Anilides - therapeutic use | Puerto Rico | Hepatitis C - drug therapy | United States | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Male | RNA, Viral - blood | Viral Load | Ritonavir - adverse effects | Time Factors | Ritonavir - therapeutic use | Adult | Female | Drug Therapy, Combination | Hepacivirus - drug effects | Antiviral Agents - therapeutic use | Europe | Ribavirin - therapeutic use | Uracil - therapeutic use | Genotype | Treatment Outcome | Macrocyclic Compounds - adverse effects | Biomarkers - blood | Macrocyclic Compounds - therapeutic use | Hepatitis C - diagnosis | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Hepacivirus - growth & development | Aged | Carbamates - therapeutic use | Uracil - analogs & derivatives | Medical colleges | Care and treatment | Proteases | Ritonavir | Biological products industry | Genetic aspects | Biological response modifiers | Hepatitis C virus | Hepatitis C | Health aspects | Ribavirin | Index Medicus | Abridged Index Medicus
Journal Article
Gastroenterology, ISSN 0016-5085, 2015, Volume 148, Issue 1, pp. 108 - 117
Background & Aims Interferon alfa–based regimens used to treat recurrent hepatitis C virus (HCV) infection after liver transplantation are poorly tolerated,... 
Gastroenterology and Hepatology | Antiviral Agent | Clinical Trial | DAA | NS5B Polymerase Inhibitor | PLUS RIBAVIRIN | ANTIVIRAL THERAPY | EFFICACY | HCV GENOTYPE 1 | MULTICENTER EXPERIENCE | COMBINATION | RECIPIENTS | PEGYLATED INTERFERON | GRAFT-SURVIVAL | GASTROENTEROLOGY & HEPATOLOGY | DRUG-DRUG INTERACTIONS | Recurrence | Prospective Studies | Antiviral Agents - pharmacokinetics | Hepatitis C - drug therapy | Liver Transplantation - adverse effects | United States | Humans | Drug Resistance, Viral | Hepacivirus - genetics | Hepacivirus - pathogenicity | Male | RNA, Viral - blood | Viral Load | Time Factors | Ribavirin - pharmacokinetics | Female | Hepatitis C - complications | Uridine Monophosphate - adverse effects | Drug Therapy, Combination | Uridine Monophosphate - therapeutic use | Hepacivirus - drug effects | Liver Neoplasms - virology | Liver Cirrhosis - diagnosis | Antiviral Agents - therapeutic use | Carcinoma, Hepatocellular - diagnosis | Ribavirin - therapeutic use | Carcinoma, Hepatocellular - surgery | Genotype | Liver Neoplasms - surgery | Treatment Outcome | Carcinoma, Hepatocellular - virology | Biomarkers - blood | Spain | New Zealand | Hepatitis C - diagnosis | Pilot Projects | Liver Cirrhosis - virology | Liver Neoplasms - diagnosis | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Liver Cirrhosis - surgery | Uridine Monophosphate - pharmacokinetics | Sofosbuvir | Virus diseases | Relapse | Liver | Transplantation | Biological response modifiers | Drug therapy | Hepatitis C virus | Health aspects | Immunosuppressive agents | Ribavirin | Diseases | Index Medicus | Abridged Index Medicus
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 2016, Volume 63, Issue 11, pp. 1405 - 1411
Background. Interferon-based hepatitis C virus (HCV) therapy is safe and effective among people receiving opioid substitution therapy (OST), but treatment... 
Hepatitis C virus | DAA | Drug use | PWID | Opioid substitution therapy | UNITED-STATES | INFECTIOUS DISEASES | METAANALYSIS | SOFOSBUVIR | MICROBIOLOGY | IMMUNOLOGY | LEDIPASVIR | HEPATITIS-C VIRUS | REINFECTION | hepatitis C virus | drug use | opioid substitution therapy | INJECT DRUGS | PEOPLE | USERS | Humans | Middle Aged | Fluorenes - therapeutic use | Hepacivirus - genetics | Male | Drug Users | Drug Therapy, Combination - adverse effects | Benzimidazoles - administration & dosage | Ribavirin - administration & dosage | Adult | Female | Fluorenes - administration & dosage | Fluorenes - adverse effects | Opiate Substitution Treatment | Retrospective Studies | Sofosbuvir - adverse effects | Benzimidazoles - adverse effects | Benzimidazoles - therapeutic use | Hepacivirus - drug effects | Sofosbuvir - therapeutic use | Data Interpretation, Statistical | Enzyme-Linked Immunosorbent Assay | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Genotype | Hepatitis C, Chronic - drug therapy | Hepatitis C, Chronic - blood | Sofosbuvir - administration & dosage | Ribavirin - adverse effects | Sustained Virologic Response | Hepatitis C, Chronic - genetics | Viral Load - drug effects | Treatment outcome | Safety and security measures | Analysis | Dosage and administration | Hepatitis C | Drug therapy | Ribavirin | Patient safety | Clinical trials | Hepatitis | Genotype & phenotype | Prescription drugs | Substance abuse treatment | Index Medicus
Journal Article
Gastroenterology, ISSN 0016-5085, 2014, Volume 146, Issue 7, pp. 1669 - 1679.e3
Background & Aims Simeprevir is an oral, once-daily inhibitor of hepatitis c virus (HCV) protease NS3/4A. We investigated the safety and efficacy of simeprevir... 
Gastroenterology and Hepatology | Drug | Chronic Hepatitis C | DAA | PROMISE | ALPHA-2A | PLUS RIBAVIRIN | VIRUS-INFECTION | TELAPREVIR | MANAGEMENT | CHRONIC HEPATITIS-C | PEGYLATED INTERFERON | BOCEPREVIR | RETREATMENT | GASTROENTEROLOGY & HEPATOLOGY | ONCE-DAILY TMC435 | Recombinant Proteins - therapeutic use | Recurrence | Simeprevir | Hepatitis C - drug therapy | Humans | Middle Aged | Hepacivirus - genetics | Polyethylene Glycols - adverse effects | Male | RNA, Viral - blood | Recombinant Proteins - adverse effects | North America | Polyethylene Glycols - therapeutic use | Viral Load | Young Adult | Time Factors | Hepatitis C - blood | Protease Inhibitors - adverse effects | Adult | Female | Drug Therapy, Combination | Protease Inhibitors - therapeutic use | Hepacivirus - drug effects | Double-Blind Method | Antiviral Agents - therapeutic use | Europe | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Treatment Outcome | Biomarkers - blood | Hepatitis C - diagnosis | Hepacivirus - enzymology | Sulfonamides - therapeutic use | Asia | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Heterocyclic Compounds, 3-Ring - adverse effects | Heterocyclic Compounds, 3-Ring - therapeutic use | Sulfonamides - adverse effects | Hepacivirus - growth & development | Viral Nonstructural Proteins - metabolism | Aged | Interferon-alpha - adverse effects | Viral Nonstructural Proteins - antagonists & inhibitors | Medical colleges | Care and treatment | Proteases | Interferon alpha | Clinical trials | Product development | Genetic aspects | Biological response modifiers | Hepatitis C virus | Hepatitis C | Health aspects | Ribavirin | Index Medicus | Abridged Index Medicus | Life Sciences
Journal Article